Genmab A/S
GMAB NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 6, 2026
ET
EPS Est.
0.37
EPS Actual
0.54
Revenue Est.
$1.12B
Revenue Actual
$1.16B
Next Earnings Report
Date
Nov 5, 2026 · Thu
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
0.36
Revenue Est.
$1.21B
Company Overview
Genmab A/S (ticker GMAB) is listed on NASDAQ with a market cap of about $20.54B. Its next earnings report (FY2026 Q3) is expected on Nov 5, 2026 (ET), Pre-market, with consensus EPS of 0.36. In the last 15 reported quarters, EPS beat consensus estimates 6 times.
Actual EPS TrendRecently15Term · Feb 22, 2023 → Aug 6, 2026
Feb 22, 2023Range: 0.05 ~ 0.65Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | 0.37 | Above forecast↑0.54 | $1.12B | $1.16B |
| May 7, 2026 | -- | 0.15 | Below forecast↓0.09 | $905.8M | $896M |
| Feb 17, 2026 | -- | 0.46 | Below forecast↓0.05 | $1.07B | $1.06B |
| Nov 6, 2025 | -- | 0.48 | Above forecast↑0.65 | $1.01B | $1.02B |
| Aug 7, 2025 | -- | 0.39 | Above forecast↑0.54 | $952.6M | $924.8M |
| May 8, 2025 | -- | 0.23 | Above forecast↑0.31 | $755.5M | $726M |
| Feb 12, 2025 | -- | 0.36 | Above forecast↑0.57 | $894.7M | $895.8M |
| Nov 6, 2024 | -- | 0.35 | Below forecast↓0.29 | $809.6M | $815.2M |
| Aug 8, 2024 | -- | 0.29 | Below forecast↓0.22 | $732.5M | $789.6M |
| May 2, 2024 | -- | 0.16 | 0.16 | $572M | $598.1M |
| Feb 14, 2024 | -- | 0.34 | 0.36 | $671.2M | $675.3M |
| Nov 7, 2023 | -- | 3.14 | Below forecast↓0.47 | $642.9M | $669.4M |
| Aug 3, 2023 | -- | 2.18 | Below forecast↓0.30 | $601.1M | $613.3M |
| May 10, 2023 | -- | 0.65 | Below forecast↓0.05 | $404.3M | $416.1M |
| Feb 22, 2023 | -- | 3.15 | Below forecast↓0.12 | $681.4M | $755M |
Original Filings (SEC)
6-K2026-08-12 ↗
6-K2026-08-11 ↗
6-K2026-08-06 ↗
6-K2026-07-15 ↗
6-K2026-06-29 ↗
6-K2026-06-17 ↗
6-K2026-06-16 ↗
6-K2026-06-15 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
